secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001193125-23-249055
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences names new CMO/President of R&D and CTO; CMO Rich transitions to advisor
--------------------------------------------------------------------------------

- J. Jill Hopkins appointed CMO and President of R&D, effective Oct 16, 2023; prior roles at Novartis, Gyroscope, Roche-Genentech.
- Mark Plavsic appointed CTO; 30 years experience including Fate Therapeutics, Sanofi Genzyme, AstraZeneca.
- Cadmus Rich resigns as CMO effective Oct 16; will serve as Senior Clinical Advisor through Nov 7, then consultant for 9 months.
- Hopkins receives annual base salary of $525k, sign-on bonus up to $200k, and equity grants of 200k options and 135k RSUs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312523249055/0001193125-23-249055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312523249055/d479220d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-249055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer